{"id":41388,"date":"2025-09-15T15:09:28","date_gmt":"2025-09-15T07:09:28","guid":{"rendered":"https:\/\/flcube.com\/?p=41388"},"modified":"2025-09-15T15:09:29","modified_gmt":"2025-09-15T07:09:29","slug":"baheals-24-take%e2%80%91over-of-tianjin-jikun-secures-rights-to-pulmonary-fibrosis-drug-jk1033","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41388","title":{"rendered":"Baheal\u2019s 24% Take\u2011over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033"},"content":{"rendered":"\n<p>China\u2011based Baheal Pharmaceutical Group (<a href=\"https:\/\/www.google.com\/finance\/quote\/301015:SHE\">SHE: 301015<\/a>) announced a strategic cooperation agreement with \u00a0Tianjin Jikun Pharmaceutical Technology Co., Ltd. Under the deal, Baheal will invest in Jikun, taking a 24\u202f% equity stake and securing exclusive rights to the advanced anti\u2011fibrotic candidate <strong>JK1033<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Equity Investment:<\/strong> Baheal acquires a 24\u202f% stake in Jikun Medicine.<\/li>\n\n\n\n<li><strong>Exclusive Rights:<\/strong> Baheal obtains full rights to JK1033, a Class\u202f1 innovative drug targeting pulmonary fibrosis.<\/li>\n\n\n\n<li><strong>Right of First Refusal:<\/strong> Baheal gains the right of first refusal\u2014on equal terms\u2014to purchase global compound rights for all remaining Jikun products.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-jk1033-a-breakthrough-anti-fibrosis-candidate\">JK1033: A Breakthrough Anti\u2011Fibrosis Candidate<\/h2>\n\n\n\n<p>JK1033 is a small\u2011molecule compound derived from traditional Chinese medicine monomers and their derivatives. Key points:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Indications:<\/strong> Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).<\/li>\n\n\n\n<li><strong>Development Milestones:<\/strong> Completed pharmacology, PK\/PD, and pre\u2011IND consultation with the U.S. FDA.<\/li>\n\n\n\n<li><strong>Clinical Progress:<\/strong> Initiated Phase\u202fI trial in China (January\u202f2025) and now poised to submit an IND application.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-baheal\">Strategic Implications for Baheal<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion:<\/strong> The acquisition adds a late\u2011stage, potentially market\u2011disruptive asset to Baheal\u2019s pipeline.<\/li>\n\n\n\n<li><strong>Global Reach:<\/strong> The right of first refusal positions Baheal to secure worldwide rights to Jikun\u2019s future assets, broadening its international footprint.<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> With a 24\u202f% stake, Baheal retains significant upside while sharing development risk with Jikun.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-implications-for-the-chinese-pharma-landscape\">Implications for the Chinese Pharma Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Collaboration:<\/strong> The deal exemplifies the growing trend of domestic pharma consolidating expertise to accelerate drug development.<\/li>\n\n\n\n<li><strong>Pulmonary Fibrosis Market:<\/strong> JK1033 may become a first\u2011in\u2011class therapy, addressing a high\u2011unmet\u2011need patient population in China and globally.<\/li>\n\n\n\n<li><strong>Regulatory Momentum:<\/strong> The timely FDA pre\u2011IND consultation signals Baheal\u2019s commitment to pursuing an international commercialization strategy.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h2>\n\n\n\n<p>Baheal\u2019s leadership emphasized that the partnership \u201caligns with our strategy to invest in high\u2011potential, late\u2011stage assets and to expand our global reach.\u201d The company expects the deal to close in the next quarter, contingent on customary regulatory approvals.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u767e\u6d0b\u533b\u836f\uff1a\u5173\u4e8e\u7b7e\u7f72\u6218\u7565\u5408\u4f5c\u534f\u8bae\u7684\u81ea\u613f\u6027\u4fe1\u606f\u62ab\u9732\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u767e\u6d0b\u533b\u836f\uff1a\u5173\u4e8e\u7b7e\u7f72\u6218\u7565\u5408\u4f5c\u534f\u8bae\u7684\u81ea\u613f\u6027\u4fe1\u606f\u62ab\u9732\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-01b3c67c-42e2-4e4f-880d-625e40319678\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u767e\u6d0b\u533b\u836f\uff1a\u5173\u4e8e\u7b7e\u7f72\u6218\u7565\u5408\u4f5c\u534f\u8bae\u7684\u81ea\u613f\u6027\u4fe1\u606f\u62ab\u9732\u516c\u544a.pdf\">\u767e\u6d0b\u533b\u836f\uff1a\u5173\u4e8e\u7b7e\u7f72\u6218\u7565\u5408\u4f5c\u534f\u8bae\u7684\u81ea\u613f\u6027\u4fe1\u606f\u62ab\u9732\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u767e\u6d0b\u533b\u836f\uff1a\u5173\u4e8e\u7b7e\u7f72\u6218\u7565\u5408\u4f5c\u534f\u8bae\u7684\u81ea\u613f\u6027\u4fe1\u606f\u62ab\u9732\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-01b3c67c-42e2-4e4f-880d-625e40319678\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Baheal Pharmaceutical Group (SHE: 301015) announced a strategic cooperation agreement with \u00a0Tianjin Jikun Pharmaceutical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41390,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[288,20,4350,24,2011],"class_list":["post-41388","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-baheal-pharmaceutical","tag-finance","tag-jikun-pharmaceutical-technology","tag-rare-orphan-disease-drugs","tag-she-301015"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Baheal\u2019s 24% Take\u2011over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Baheal Pharmaceutical Group (SHE: 301015) announced a strategic cooperation agreement with \u00a0Tianjin Jikun Pharmaceutical Technology Co., Ltd. Under the deal, Baheal will invest in Jikun, taking a 24\u202f% equity stake and securing exclusive rights to the advanced anti\u2011fibrotic candidate JK1033.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41388\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Baheal\u2019s 24% Take\u2011over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41388\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-15T07:09:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-15T07:09:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1503.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41388#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41388\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Baheal\u2019s 24% Take\u2011over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033\",\"datePublished\":\"2025-09-15T07:09:28+00:00\",\"dateModified\":\"2025-09-15T07:09:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41388\"},\"wordCount\":340,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41388#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1503.webp\",\"keywords\":[\"Baheal Pharmaceutical\",\"Finance\",\"Jikun Pharmaceutical Technology\",\"Rare \\\/ orphan disease drugs\",\"SHE: 301015\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41388#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41388\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41388\",\"name\":\"Baheal\u2019s 24% Take\u2011over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41388#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41388#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1503.webp\",\"datePublished\":\"2025-09-15T07:09:28+00:00\",\"dateModified\":\"2025-09-15T07:09:29+00:00\",\"description\":\"China\u2011based Baheal Pharmaceutical Group (SHE: 301015) announced a strategic cooperation agreement with \u00a0Tianjin Jikun Pharmaceutical Technology Co., Ltd. Under the deal, Baheal will invest in Jikun, taking a 24\u202f% equity stake and securing exclusive rights to the advanced anti\u2011fibrotic candidate JK1033.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41388#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41388\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41388#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1503.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1503.webp\",\"width\":1080,\"height\":608,\"caption\":\"Baheal\u2019s 24% Take\u2011over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41388#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Baheal\u2019s 24% Take\u2011over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Baheal\u2019s 24% Take\u2011over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033 - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Baheal Pharmaceutical Group (SHE: 301015) announced a strategic cooperation agreement with \u00a0Tianjin Jikun Pharmaceutical Technology Co., Ltd. Under the deal, Baheal will invest in Jikun, taking a 24\u202f% equity stake and securing exclusive rights to the advanced anti\u2011fibrotic candidate JK1033.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41388","og_locale":"en_US","og_type":"article","og_title":"Baheal\u2019s 24% Take\u2011over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=41388","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-15T07:09:28+00:00","article_modified_time":"2025-09-15T07:09:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1503.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41388#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41388"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Baheal\u2019s 24% Take\u2011over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033","datePublished":"2025-09-15T07:09:28+00:00","dateModified":"2025-09-15T07:09:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41388"},"wordCount":340,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41388#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1503.webp","keywords":["Baheal Pharmaceutical","Finance","Jikun Pharmaceutical Technology","Rare \/ orphan disease drugs","SHE: 301015"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41388#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41388","url":"https:\/\/flcube.com\/?p=41388","name":"Baheal\u2019s 24% Take\u2011over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41388#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41388#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1503.webp","datePublished":"2025-09-15T07:09:28+00:00","dateModified":"2025-09-15T07:09:29+00:00","description":"China\u2011based Baheal Pharmaceutical Group (SHE: 301015) announced a strategic cooperation agreement with \u00a0Tianjin Jikun Pharmaceutical Technology Co., Ltd. Under the deal, Baheal will invest in Jikun, taking a 24\u202f% equity stake and securing exclusive rights to the advanced anti\u2011fibrotic candidate JK1033.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41388#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41388"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41388#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1503.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1503.webp","width":1080,"height":608,"caption":"Baheal\u2019s 24% Take\u2011over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41388#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Baheal\u2019s 24% Take\u2011over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1503.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41388"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41388\/revisions"}],"predecessor-version":[{"id":41391,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41388\/revisions\/41391"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41390"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41388"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41388"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}